Jefferson, Sarah J.
Gregg, Ian
Dibbs, Mark http://orcid.org/0000-0002-4341-361X
Liao, Clara
Wu, Hao
Davoudian, Pasha A. http://orcid.org/0000-0002-5096-7610
Woodburn, Samuel C.
Wehrle, Patrick H.
Sprouse, Jeffrey S.
Sherwood, Alexander M.
Kaye, Alfred P. http://orcid.org/0000-0002-3153-1221
Pittenger, Christopher http://orcid.org/0000-0003-2117-9321
Kwan, Alex C. http://orcid.org/0000-0003-2169-1667
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (R01MH121848, R01MH128217)
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health
Article History
Received: 2 November 2022
Revised: 26 February 2023
Accepted: 20 March 2023
First Online: 4 April 2023
Competing interests
: ACK is a member of the Scientific Advisory Board of Empyrean Neuroscience and Freedom Biosciences. ACK has consulted for Biohaven Pharmaceuticals. No-cost compounds were provided to ACK for research by Usona Institute. CP has served as a consultant in the past year for Biohaven Pharmaceuticals, Teva Pharmaceuticals, and Brainsway Therapeutics and has performed research under contract with Biohaven and with Blackthorn Therapeutics, Ltd., on unrelated projects. CP and APK have performed research under contract with Transcend Therapeutics on unrelated projects. CP and SJJ have a sponsored research agreement with Freedom Biosciences. The sponsor of this research was not involved in the analyses or writing of the manuscript. The duties had no influence on the content of this article. The remaining authors have nothing to disclose.